Abstract
The contribution of fungal infections to the morbidity and mortality of HIV-infected individuals is largely unrecognized. A recent meeting highlighted several priorities that need to be urgently addressed, including improved epidemiological surveillance, increased availability of existing diagnostics and drugs, more training in the field of medical mycology, and better funding for research and provision of treatment, particularly in developing countries.
Original language | English |
---|---|
Pages (from-to) | 107-109 |
Number of pages | 3 |
Journal | Trends in Microbiology |
Volume | 22 |
Issue number | 3 |
Early online date | 26 Feb 2014 |
DOIs | |
Publication status | Published - Mar 2014 |
Bibliographical note
Copyright © 2014 Elsevier Ltd. All rights reserved.Acknowledgments
We thank the following for their support of the workshop held in Cape Town in July 2013: Associates of Cape Cod, Cepheid, Clinical Infectious Diseases Research Initiative, Company of Biologists, Department of Science and Technology (Republic of South Africa), Elsevier, European Molecular Biology Organization (EMBO), Fungal Infection Trust, Gilead, Immuno-Mycologics, International Society for Human and Animal Mycology, Merck Sharp & Dohme (MSD), Miravista Diagnostics, National Research Foundation of South Africa, South African Immunology Society, Scientific Group, University of Cape Town, Wellcome Trust, and Zeiss.
Keywords
- HIV
- AIDS
- fungal infection
- mortality
- translational research
- immunity